Newsfeeds - Spark Newswire

1 minute read

Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion

Today, 5:12 AM

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to…

MRNS

1 minute read

Merus Highlights Publication In Nature Communications On MCLA-145’s Novel Mechanism Of Action Promoting Tumor Immunity And Context Dependent T-Cell Costimulation

By Bill Haddad

Today, 5:12 AM

Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the novel mechanism of action (MOA) of

MRUS

3 minute read

Merus Presents Clinical Data On Zenocutuzumab In NRG1-fusion (NRG1+) Cancers At 2021 ASCO Meeting

By Benzinga Newsdesk

Today, 5:12 AM

Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and

MRUS

7 minute read

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes

By Shanthi Rexaline

Today, 5:12 AM

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.

ADAP

5 minute read

Uncategorized

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:12 AM

Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday.

ADAP

2 minute read

Uncategorized

Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021

By Benzinga Newsdesk

Today, 5:12 AM

Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html BeiGene (BGNE)

ADAP

1 minute read

Uncategorized

Merus Q1 EPS $(0.28) Up From $(0.68) YoY, Sales $8.35M Up From $6.30M YoY

By Benzinga Newsdesk

Today, 5:12 AM

Merus (NASDAQ:MRUS) reported quarterly losses of $(0.28) per share. This is a 58.82 percent increase over losses of $(0.68) per share from the same period last year. The company reported $8.35 million in sales this

MRUS